The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Open accessAbstract
BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion regimen termed STRIDE (Single Tremelimumab Regular Interval Durvalumab), showed encouraging clinical activity and safety in a phase 2 trial of unresectable hepatocellular carcinoma. METHODS: In this global, open-label, phase 3 trial, the majority of the patients we enrolled with unresectable hepatocellular carcinoma and no previous systemic treatment were randomly assigned to receive one of three regimens: tremelimumab (300 mg, one dose) plus durvalumab (1500 mg every 4 weeks; STRIDE), durvalumab (1500 mg every 4 weeks), or sorafenib (400 mg twice daily). The primary objective was overall survival for STRIDE versus sorafenib. Noninferiority for overall survival for durvalumab versus sorafenib was a secondary objective. RESULTS: In total, 1171 patients were randomly assigned to STRIDE (n=393), durvalumab (n=389), or sorafenib (n=389). The median overall survival was 16.43 months (95% confidence interval [CI], 14.16 to 19.58) with STRIDE, 16.56 months (95% CI, 14.06 to 19.12) with durvalumab, and 13.77 months (95% CI, 12.25 to 16.13) with sorafenib. Overall survival at 36 months was 30.7%, 24.7%, and 20.2%, respectively. The overall survival hazard ratio for STRIDE versus sorafenib was 0.78 (96.02% CI, 0.65 to 0.93; P=0.0035). Overall survival with durvalumab monotherapy was noninferior to sorafenib (hazard ratio, 0.86; 95.67% CI, 0.73 to 1.03; noninferiority margin, 1.08). Median progression-free survival was not significantly different among all three groups. Grade 3/4 treatment-emergent adverse events occurred for 50.5% of patients with STRIDE, 37.1% with durvalumab, and 52.4% with sorafenib. CONCLUSIONS: STRIDE significantly improved overall survival versus sorafenib. Durvalumab monotherapy was noninferior to sorafenib for patients with unresectable hepatocellular carcinoma. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03298451.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The response rate was 20% with durvalumab plus tremelimumab and 30% with atezolizumab plus bevacizumab, with median duration of response ranging from 18 months to 22 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-L1 inhibitor-based regimens received approvals in 2020 (atezolizumab plus bevacizumab) and 2022 (tremelimumab plus durvalumab) as first-line treatment options for unresectable hepatocellular carcinoma after showing improved outcomes over sorafenib, with median overall survival ranging from 16 months to 19 months.”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With the introduction of PD-L1 inhibitors in this setting, survival benefits versus sorafenib were improved with a median overall survival of 19•2 months with atezolizumab plus bevacizumab, 9,10 16•6 months with durvalumab monotherapy, and 16•4 months with tremelimumab plus durvalumab, 7,8 leading to regulatory”
From Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At the RP2D, the safety profile was consistent with the known safety profile of durvalumab in combination with tremelimumab in adult patients (13, 14), and no new safety signals were identified in our pediatric population.”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“durvalumab plus tremelimumab has demonstrated improved OS compared with sorafenib alone in adults with unresectable hepatocellular cancer (14).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“In HIMALAYA, durvalumab plus tremelimumab yielded an objective response rate of 20% and median duration of response of 22•3 months.7”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68]”
From Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis (2025) · cites this paper as [68]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Self-citationSchadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,001
Xu, C., Sun, J., Liang, Q., Zhao, H., & Pan, J. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.01.012 · Cited by 3
Tovoli, F., Iavarone, M. A., Cabibbo, G., Marra, F., Vivaldi, C., Dalbeni, A., Ponziani, F. R., Palloni, A., Bergamo, F., Rimassa, L., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001725 · Cited by 3
Self-citationYum, S., Rodríguez-García, A., Castellsagué, J., Giménez-Alejandre, M., Colell, G., Colell, S., Lobo‐Jarne, T., LaRue, M. A., Minnier, M. A., Yazicioglu, M. N., et al. (2026) · JCI Insight · doi:10.1172/jci.insight.197404 · Cited by 3
“Despite the recent inclusion of PD-1/PD-L1–blocking antibodies with CTLA-4 or VEGF-A blockade as first-line therapy for advanced HCC — following superior activity over sorafenib — only 17%–36% of patients respond to these therapies (59–61).”
Sayadi, A., Campani, C., Laurent-Bellue, A., Ziol, M., Tommaso, L. D., Becht, É., Terris, B., Caldéraro, J., Messerini, L., Albuquerque, M., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101874 · Cited by 3
Self-citationGorgulho, J., Masood, R., Buescher, G., Giehren, F., Salié, H., David, D., Pagani, F., Kocheise, L., Schmidt, C., Waldmann, M., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337617 · Cited by 4
Seung, S. J., Saherawala, H., Kim, Y.-J., Tieu, J., Wang, S., Shephard, C. S., & Bossé, D. (2024) · Cancers · doi:10.3390/cancers16122232 · Cited by 3
Maruta, S., Koshima, Y., Tsuchiya, T., Tamura, R., Takahashi, M. P., Ohshima, T., & Ooka, Y. (2024) · Cureus · doi:10.7759/cureus.66185 · Cited by 3
Shirota, G., Sato, S., Yasunaga, H., Aso, S., Akahane, M., Itoh, D., & Abe, O. (2024) · Japanese Journal of Radiology · doi:10.1007/s11604-024-01640-1 · Cited by 3
Zhou, C., Jiang, J., Xiang, X., Liu, H., Wu, G., Zeng, R., Lu, T., Zhang, M., Shen, Y., Hong, M., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00567-7 · Cited by 3
Pathogenesis and Systemic Treatment of Hepatocellular Carcinoma: Current Status and Prospects
Lei, W., Zhou, K., Lei, Y., Li, Q., & Zhu, H. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0403 · Cited by 5
Nagashima, S., Kobayashi, S., Tsunoda, S., Yamachika, Y., Tozuka, Y., Fukushima, T., Morimoto, M., Ueno, M., Furuse, J., & Maeda, S. (2024) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-024-02062-2 · Cited by 3
Self-citationCombining epigenetic modulation: the next step for HCC immunotherapy?
Ma, C., & Bengsch, B. (2024) · Gut · doi:10.1136/gutjnl-2024-334033 · Cited by 3
Tsurusaki, M., Sofue, K., Murakami, T., & Tanigawa, N. (2024) · Cancers · doi:10.3390/cancers17010101 · Cited by 3
“In addition, there is a new regimen following the results of the HIMALAYA trial [42], durvalumab + tremelimumab, a treatment with the anti-PD-L1 + anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) combination.”
Komatsu, S., Yano, Y., Terashima, K., Fujishima, Y., Ishida, J., Ishihara, N., Matsuura, T., Okimoto, T., Kodama, Y., & Fukumoto, T. (2025) · Surgery Today · doi:10.1007/s00595-025-03009-x · Cited by 3
“According to the randomized phase III trial of lenvatinib in the REFLECT trial and tremelimumab plus durvalumab in the HIMALAYA trial [17, 18], patients with macrovascular invasion (Vp4) were excluded from the entry criteria.”
Wu, G., Liu, Y., Fan, H., Rao, M., Zhang, J., & Zhang, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02171-5 · Cited by 3
“The results of this study showed that the PFS and OS in the TAR group were longer than that in the TA group, and 4.2–7.2 and 4.6 months longer, respectively, than those reported previously [8–10].”
InfluentialYang, G., Ren, Y., Li, Y., Tang, Y., Yuan, F., Cao, M., He, Z., Su, X., Shi, Z., Shi, Z., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104737 · Cited by 3
Zhang, Y., Wu, X., Yi, J., Xu, J., Zhang, Y.-N., Lyu, N., & Zhao, M. D. (2025) · Liver Cancer · doi:10.1159/000545891 · Cited by 3
Huang, K. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.038 · Cited by 3
Immunotherapy in hepatocellular carcinoma
Martín, A. J. M., Alsar, J. S., Cañete, M. A., Lama, C. C., & Morán, L. O. (2025) · Revisiones en cáncer · doi:10.20960/revcancer.00110 · Cited by 3
Lee, P., Wu, C.-J., Lee, I., Lee, C.-J., Hou, M., & Huang, Y. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101491 · Cited by 3
Ishii, T., Shindoh, J., Nakamura, I., Hirono, S., Wakasugi, M., Ichida, A., Hamada, T., Matsushima, H., Nishio, T., Tokumitsu, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70027 · Cited by 3
Suzuki, Y., Kuzuya, T., Osawa, L., Komiyama, Y., Takada, H., Matsuda, S., Muraoka, M., Sato, M., Maekawa, S., Enomoto, N., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70024 · Cited by 3
Radiomics of hepatopancreatobiliary cancer diagnosis, management, and future prospects
Koku, D., Agarwala, Y., Vithayathil, M. K., Tait, P., Aboagye, E. O., & Sharma, R. (2025) · Clinical Radiology · doi:10.1016/j.crad.2025.107167 · Cited by 3
Sakane, T., Tada, T., Tei, H., Kushida, S., Momose, K., Hirano, H., Nishioka, C., Yagi, Y., Yamamoto, A., Matono, T., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70077 · Cited by 4
Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Ryan, C. E., Lambdin, J. T., Shah, S. A., Quillin, R. C., Lemon, K. H., Hernandez, J. M., & Sohal, D. P. S. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-12811-7 · Cited by 3
“Recent randomized controlled trials have demonstrated improved overall survival for patients with unresectable HCC treated with tremelimumab in combination with durvalumab when compared with those treated with sorafenib alone.(6) However, the use of drugs to activate the”
BackgroundZhou, J. Y., Eder, D., Weber, F., Heumann, P., Kronenberg, K., Werner, J. M., Geissler, E. K., Schlitt, H. J., Hutchinson, J. A., & Bitterer, F. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1211916 · Cited by 3
“…gain regulatory approval for treatment of non-resectable HCC. Recently, the FDA approved of the combination of durvalumab, an anti PD-L1 antibody, and tremelimumab, an anti-CTLA-4 antibody, after the HIMALAYA Study showed an improvement in overall survival for patients with non-resectable HCC (33).”
BackgroundBeyond the Horizon: A Cutting-Edge Review of the Latest Checkpoint Inhibitors in Cancer Treatment
Boutros, M., Attieh, F., Chartouni, A., Jalbout, J., & Kourié, H. R. (2023) · Cancer Investigation · doi:10.1080/07357907.2023.2267675 · Cited by 3
Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials
Gamboa, A. C., Kooby, D. A., Maithel, S. K., & Gamblin, T. C. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27545 · Cited by 3
Abe, H., Endo, K., Kuroda, H., Oikawa, T., Abe, T., Ito, A., Suzuki, A., Yoshida, Y., Kakisaka, K., & Matsumoto, T. (2024) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01901-y · Cited by 3
Colloca, G. A., & Venturino, A. (2024) · Cancer · doi:10.1002/cncr.35199 · Cited by 3
“35 However, the control arms of the most recent studies have detected increased PPS even after first ‐ line treatment with tyrosine kinase inhibitors (TKIs) alone; second ‐ line therapies could certainly have contributed to this phenomenon along with other variables that are still little evaluated,…”
BackgroundMethodInfluentialPrecision Oncology in Hepatopancreatobiliary Cancer Surgery
Newhook, T. E., Tsai, S., & Meric‐Bernstam, F. (2026) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.026 · Cited by 3
Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
Goyal, P. K., & Sangwan, K. (2024) · Current Pharmacology Reports · doi:10.1007/s40495-024-00351-5 · Cited by 3
S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0
Groß, S., Bitzer, M., Albert, J., Blödt, S., Boda‐Heggemann, J., Brunner, T. B., Caspari, R., Toni, E. D., Dombrowski, F., Evert, M., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2189-8567 · Cited by 3
Self-citationImmune-mediated hepatitis: Basic concepts and treatment
Velasco, J. A. V.-R., Calderón, D. K. T., Cerpa‐Cruz, S., Chávez, J. A. V., Martínez, J. F. U., García-Jiménez, E. S., Ledesma, J. M. A., Díaz‐González, Á., & Crespo, J. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2023.12.001 · Cited by 3
SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know
Gutman, M. J., Serra, L. M., Koshy, M., & Katipally, R. R. (2024) · Seminars in Interventional Radiology · doi:10.1055/s-0043-1778657 · Cited by 3
Ishihara, N., Komatsu, S., Kido, M., Gon, H., Fukushima, K., Urade, T., Yoshida, T., Arai, K., Yanagimoto, H., Toyama, H., et al. (2024) · Oncology Letters · doi:10.3892/ol.2024.14465 · Cited by 3
Advancing Radioembolization Through Personalized Dosimetry
Young, S. J., Goldberg, D., Hannallah, J. R., Struycken, L., & Woodhead, G. J. (2024) · Advances in Clinical Radiology · doi:10.1016/j.yacr.2024.04.004 · Cited by 3
Brown, T. J., Gimotty, P. A., Mamtani, R., Karasic, T. B., & Yang, Y. (2024) · JCO Clinical Cancer Informatics · doi:10.1200/cci.23.00220 · Cited by 3
“24 This present analysis is not without limitations and should be interpreted with caution.”
Ruff, S. M., & Pawlik, T. M. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.59 · Cited by 3
Kang, J. G., Han, K., Chung, T., & Rhee, H. (2024) · European Journal of Radiology · doi:10.1016/j.ejrad.2024.111772 · Cited by 3
Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease
Rzeniewicz, K., & Sharma, R. (2024) · World Journal of Clinical Oncology · doi:10.5306/wjco.v15.i11.1394 · Cited by 3
Uchikawa, S., Kawaoka, T., Murakami, S., Miura, R., Shirane, Y., Johira, Y., Kosaka, M., Fujii, Y., Fujino, H., Ono, A., et al. (2024) · Hepatology Research · doi:10.1111/hepr.14130 · Cited by 3
“…a programmed cell death ligand 1 inhibitor, and tremelimumab, a cytotoxic T - lymphocyte - associated antigen 4 inhibitor, was approved for patients with unresectable HCC based on the results of the HIMA-LAYA study, 13 and systemic treatment for unresectable HCC has changed to immune therapy.”
Giudicelli, H., Conti, F., Scatton, O., Thabut, D., Allaire, M., Arcile, G., Bijot, M. A. J. C., Boughdad, S., Bouzbib, C., Brisson, H., et al. (2024) · Journal of Liver Transplantation · doi:10.1016/j.liver.2024.100252 · Cited by 3
Current Treatment Paradigm and Approach to Advanced Hepatocellular Carcinoma
Patresan, J., Patel, H., Chandrasekaran, K., & Reynolds, G. (2024) · Cureus · doi:10.7759/cureus.75471 · Cited by 3
“Durvalumab alone was also deemed to be non-inferior to sorafenib [63].”
Li, J., Liao, C., Liu, Z., Xiong, H., Cai, J., & Liu, T. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241305700 · Cited by 4
Tsilimigras, D. I., Stecko, H., Moris, D., & Pawlik, T. M. (2024) · HPB · doi:10.1016/j.hpb.2024.12.008 · Cited by 3
Fan, Y., Xiao, H., Wang, Y., Wang, S.-H., & Sun, H. (2024) · Discover Oncology · doi:10.1007/s12672-024-01735-1 · Cited by 3
“This combination therapy reduced the risk of death by 22% compared to sorafenib monotherapy [9].”
de la Cruz‐Ojeda, P., Navarro‐Villarán, E., Fuertes‐Agudo, M., Mata, A., López‐Lluch, G., Navas, P., Cadenas, S., Casado, M., & Muntané, J. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.12.053 · Cited by 3
Epidemiological characteristics of contemporary patients with untreated hepatocellular carcinoma.
González-Sánchez, H., Castaño‐García, A., Celada-Sendino, M., Flórez-Diez, P., García-Calonge, M., Rodríguez, M., Chiminazzo, V., & Calvo, M. V. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11029/2024 · Cited by 3
Saeed, A., Colby, S., Oberstein, P. E., Duda, D. G., Park, R., Agarwal, R., Figueroa-Moseley, C., Vaidya, R., Unger, J. M., Guthrie, K. A., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2485020 · Cited by 3
Role of Immunotherapy in the Treatment of Hepatocellular Carcinoma
Dobrosotskaya, I. Y., Kumar, R. K., & Frankel, T. L. (2025) · Current Oncology · doi:10.3390/curroncol32050264 · Cited by 3
“Himalaya was a global, open-label phase 3 trial with one of the treatment arms including single-agent durvalumab [10].”
InfluentialChen, S., Yu, W., Wang, X. J., & Liu, W. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2516994 · Cited by 3
“…overall survival. the objec-tive response rate among the patients in the tremelimumab-plus-durvalumab group was 20.1%, as stated in reference [24]. this finding suggests that the combination therapy of tremelimumab and durvalumab offers a more favorable treatment option for patients in terms…”
InfluentialChiu, S.-H., Kesselman, A. J., Delitto, D., Dhanasekaran, R., Chang, W., Kamaya, A., & Tse, J. R. (2025) · American Journal of Roentgenology · doi:10.2214/ajr.25.33389 · Cited by 3
Two Milestone Studies in Liver Cancer Immunotherapy
Greten, T. F., & Monge, C. (2022) · NEJM Evidence · doi:10.1056/evide2200140 · Cited by 3
Cabibbo, G., & Edeline, J. (2023) · Liver International · doi:10.1111/liv.15513 · Cited by 3
Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
Shiina, S., Maruyama, H., Tobari, M., & Yamashita, T. (2023) · Hepatology International · doi:10.1007/s12072-023-10533-w · Cited by 3
“Following Atezo/Beva, three other combination immunotherapies, sintilimab plus a bevacizumab biosimilar (ORIENT-32) [2], tremelimumab plus durvalumab (HIMALAYA) [3], atezolizumab plus cabozantinib (COSMIC-312) [4], have shown survival benefits as first line systemic therapy for unresectable HCC. Systemic therapy for H…”
BackgroundBiswas, S., & Samanta, A. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i14.103267 · Cited by 3
Establishing five-year overall survival as a new standard for trials in advanced HCC
Nahon, P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.05.001 · Cited by 3
Dhyani, A., & Harding, J. J. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012658 · Cited by 3
Adhoute, X., Gonzalez, A., Lévi‐Strauss, T., Mineur, L., Pénaranda, G., Sellier, F., Toullec, C., Pietri, O., Castellani, P., Tran, A., et al. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002830 · Cited by 3
“Some of these bleeding complications should be avoided by using the combination of anti-PDL1 plus anti-CTL4 [7].”
Nault, J., Sritharan, N., Verset, G., Borbath, I., Lequoy, M., Allaire, M., Regnault, H., Colle, I. O., Orlent, H., Sinapi, I., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101192 · Cited by 2
Saccenti, L., Varble, N., Borde, T., Mikhail, A. S., Kassin, M. T., Levy, E. B., Xu, S., Hazen, L., Ukeh, I. N., Vasco, C., et al. (2024) · La radiologia medica · doi:10.1007/s11547-024-01937-1 · Cited by 2
Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma
Lian, D., Gan, Y., Xiao, D., Xuan, D., Liu, S., & Wei, Y. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16367 · Cited by 2
Effect of immune checkpoint inhibitors on patients with hepatitis B virus infection
Mon, H.-C., Lee, P., Chi, C., & Huang, Y. (2024) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001202 · Cited by 2
“33 ICIs are now used in numerous cancer treatments, including unresectable HCC, with increased use in the neoadjuvant and adjuvant settings.”
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Groß, S., Bitzer, M., Albert, J., Blödt, S., Boda‐Heggemann, J., Borucki, K., Brunner, T. B., Caspari, R., Dombrowski, F., Evert, M., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2460-6347 · Cited by 3
Self-citationS3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Bitzer, M., Groß, S., Albert, J., Blödt, S., Boda‐Heggemann, J., Borucki, K., Brunner, T. B., Caspari, R., Dombrowski, F., Evert, M., et al. (2025) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2460-6298 · Cited by 4
Self-citationAnders, M. M., de Mattos, Â. Z., Debes, J. D., Beltrán, O., Coste, P., Marín, J. I., Chagas, A. L., Menéndez, J., Estupiñán, E. C., Ferrer, J. D., et al. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101905 · Cited by 2
“Studies with other tumors show that T-cell clonal activation and expansion are better achieved when ICI is administered before tumor removal.”
Liu, G., Guo, R., & Xu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1520055 · Cited by 2
Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinoma
Chuang, C.-H., Chen, C.-T., Hsu, C., & Shao, Y. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04052-w · Cited by 2
Influence of the gut microbiota on the response to immunotherapy in hepatocellular carcinoma
Wu, X., & Lee, T. K. (2025) · Hepatoma Research · doi:10.20517/2394-5079.2025.07 · Cited by 2
Rossari, F., Lavacchi, D., Alimenti, E., Soldà, C., Salani, F., Esposito, L., Foti, S., Camera, S., Persano, M., Prinzi, F. L., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100186 · Cited by 2
“Unpostponable procedures requiring bevacizumab interruption, such as endoscopic variceal ligation, may suggest the use of other validated fi rst-line treatments lacking antiangiogenic drugs, such as the STRIDE regimen, 36,37 to avoid eBEVmod in the AtezBev strategy.”
Shivega, W. G., Wang, X. W., & Behrens, S. (2025) · Journal of Liver Transplantation · doi:10.1016/j.liver.2025.100285 · Cited by 4
Lv, L., Ren, S., Zhang, Z., Lin, H., & Liu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1522945 · Cited by 2
Ly, N., Ramgoolam, S. D., & Ganesan, A. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00863 · Cited by 2
Koroki, K., Ogasawara, S., Yumita, S., Nakagawa, M., Kanzaki, H., Kobayashi, K., Inoue, M., Nakamura, M., Kanogawa, N., Kondo, T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101509 · Cited by 2
Krishnamurthy, N., Cherry, D. R., Rodriguez-Russo, C. A., & Buckstein, M. H. (2025) · Advances in Radiation Oncology · doi:10.1016/j.adro.2025.101856 · Cited by 2
Kulkarni, A. V., Singal, A. G., & Reddy, K. R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70333 · Cited by 2
“ICIs alone have been reported to provide an objective response rate of 20%–25% [13, 52].”
Lee, K., Kim, S., Zhao, J., & Neo, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1631258 · Cited by 2
Interpreting immunogenicity in oncology clinical trials
Galle, P. R., Reck, M., Pinato, D. J., García‐Campelo, R., Finn, R. S., Cousin, S., Zanghi, J., Bernaards, C. A., Swanson, S. J., Morris, S., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103016 · Cited by 2
Self-citationImmune checkpoints in hepatocellular carcinoma and the challenges of therapeutic resistance
Tao, X., & Yang, X. (2025) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2025.2542137 · Cited by 3
Charoenthanadhol, T., Phetcharaburanin, J., Bubpamala, T., Sookprasert, A., Chindaprasirt, J., Sanlung, T., Watcharenwong, P., Putraveephong, S., & Wirasorn, K. (2025) · Cancers · doi:10.3390/cancers17172915 · Cited by 2
“[6,7].”
Hatanaka, T., Yata, Y., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70033 · Cited by 2
Self-citationRefining the role of liver transplantation as a curative treatment for hepatocellular carcinoma
Yoh, T., Ito, T., Ogiso, S., Uchida, Y., Ishii, T., & Hatano, E. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02898-9 · Cited by 2
Wu, S., Chen, X., Ji, Y., Zhang, C., Xie, Y., & Liang, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1697608 · Cited by 2
Yan, H., Li, Y., Guo, B., Yang, B. Y., & Tang, D. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1674965 · Cited by 2
“Recent years have witnessed signi fi cant advances beyond targeted therapy, with emerging evidence demonstrating the ef fi cacy of both immunotherapy monotherapy (14) and immune-targeted combinations (15), which have been incorporated into the NCCN (2024) guidelines.”
Chen, C.-T., Chuang, C.-H., Hsu, C., & Shao, Y. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s548785 · Cited by 2
Top advances of the year: Reappraisal of systemic versus local therapy for hepatocellular carcinoma
Oyenuga, M., McGrew, T., Hannan, L. M., & Alese, O. B. (2025) · Cancer · doi:10.1002/cncr.70162 · Cited by 2
Michalski, K., Reiter, F. P., Kosmala, A., Hartrampf, P. E., Seifert, S., Kalogirou, C., Kircher, S., Bley, T. A., Geier, A., Meining, A. G., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270755 · Cited by 2
Pricing Trends and Overlapping Indications of Checkpoint Inhibitors for Cancer Treatment
Paul, J., Mitchell, A. P., Kesselheim, A. S., & Rome, B. N. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00099 · Cited by 2
Zhou, Y., Yao, M., Ma, J., Wen, T., & Zhang, X.-Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003918 · Cited by 2
Celsa, C., Pressiani, T., Nishida, N., Chamseddine, S., Arvind, A., Li, M., Fortuny, M., Khaled, N. B., Iavarone, M. A., Toyoda, H., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101685 · Cited by 2
“The incidence of grade 3-4 TRAEs (16.3% overall) was lower than the 25.4% reported in the HIMALAYA trial (4), potentially reflecting differences in adverse event reporting between clinical trials and real-world practice.”
InfluentialSelf-citationSasaki, A., Kimura, R., & Okamoto, R. (2025) · Cureus · doi:10.7759/cureus.97530 · Cited by 2
External beam radiation for HCC: Ready for incorporation into guidelines?
Buckstein, M. H., & Dawson, L. A. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101683 · Cited by 2
“Of note, the HIMALAYA trial (durvalumab and tremelimumab vs. sorafenib) excluded Vp4 PVT. 30 While the exact cause of the poorer outcomes is unclear, patients with Vp4 PVT likely have only a small window in which to respond to immuno-therapy; if they do not respond, they often experience rapid…”
InfluentialRojas, M., Acosta, L., & Brito, E. (2025) · Asian journal of Current Research in Clinical Cancer · doi:10.51847/kxa9rvrxpc · Cited by 2
Kelley, R. K., Lee, Y. S., Conway, J., Kurland, J. F., & Mccoon, P. E. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1592 · Cited by 2
Self-citationGao, X., Sun, Y., Huang, J., Xu, L., Huang, H., & Yang, Z. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1721263 · Cited by 2
Yu, X., Zhang, X., Jiang, O., Li, X., Chen, G., Li, X., Xu, Y., Lin, S., Yuan, G., & Cui, R. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000004386 · Cited by 2
Kim, G., Kang, B., Hong, J. Y., Kang, H., Kim, J., Hwang, S., Lee, S. H., Jung, S. H., An, C., Lee, W. S., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01207-x · Cited by 2
Self-citationTerashima, T., Sanada, H., Takata, N., Hayashi, T., Seki, A., Nakagawa, H., Toyama, T., Nakanuma, S., Makino, I., Yasumoto, K., et al. (2025) · Hepatology Research · doi:10.1111/hepr.70099 · Cited by 2
Response evaluation to systemic therapy in HCC: Current challenges and future perspectives
Matute‐González, M., Ronot, M., Chernyak, V., Sangro, B., & Rimola, J. (2025) · Hepatology · doi:10.1097/hep.0000000000001621 · Cited by 3
“%) treated with nivolumab presented with pseudo-progression according to a multicenter study, [68] no pseudoprogression was reported in the main RCTs assessing immunotherapy for HCC, [15,16,69 – 71] which questions the need for iRECIST in this context.”
InfluentialSelf-citation
Metadata
- Authors
- Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., Rimassa, L., Breder, V., Vasilyev, A., Heurgué, A., Tam, V. C., Mody, K., Thungappa, S. C., Ostapenko, Y., Yau, T., Azevedo, S., Varela, M., Cheng, A.-L., Qin, S., Galle, P. R., Ali, S., Marcovitz, M., Makowsky, M., He, P., Kurland, J. F., Negro, A., & Sangro, B.
- Affiliations
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
- Humanity & Health (CN)
- Kindai University Hospital (JP)
- Chinese University of Hong Kong (HK)
- University of California, San Francisco (US)
- Kyorin University (JP)
- Khon Kaen University (TH)
- Asan Medical Center (KR)
- Cancer Research and Clinical Trials Center, Department of Optimal Therapy, National Cancer Hospital, Hanoi, Vietnam
- Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany
- Humanitas University (IT)
- Russian Cancer Research Center NN Blokhin (RU)
- Department of Oncology, Railway Clinical Hospital, St. Petersburg, Russia
- Department of Hepato-Gastroenterology, Robert-Debré Hospital, Reims, France
- University of Calgary (CA)
- Mayo Clinic (US)
- Sri Venkateshwara Hospital, Bangalore, India
- National Cancer Institute (UA)
- Queen Mary Hospital (CN)
- Unidade de Pesquisa em Oncologia Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Liver Unit, Hospital Universitario Central de Asturias, Universidad de Oviedo, Instituto Universitario de Oncología del Principado de Asturias–Obra Social Cajastur, Instituto de Investigación Sanitaria del Principado de Asturias, Fundación para la Investigación y la Innovación Biosanitaria del Principado de Asturia, Oviedo, Spain
- National Taiwan University (TW)
- 81th Hospital of PLA (CN)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- AstraZeneca (United States) (US)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- ORCID
- Lau, George
- Kudo, Masatoshi
- Chan, Stephen L.
- Kelley, Robin Kate
- Furuse, Junji
- Sukeepaisarnjaroen, Wattana
- Kang, Yoon-Koo
- Rimassa, Lorenza
- Breder, Valeriy
- Heurgué, Alexandra
- Tam, Vincent C.
- Mody, Kabir
- Yau, Thomas
- Cheng, Ann-Lii
- Qin, Shukui
- Galle, Peter R.
- Marcovitz, Michelle
- He, Philip
- Kurland, John F.
- Negro, Alejandra
- Sangro, Bruno
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-26
- Volume
- 1
- Issue
- 8
- Pages
- EVIDoa2100070-EVIDoa2100070
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4281645619
- Cited by
- 1,576
- References
- 23
- Citations by year
- 2026: 356 · 2025: 450 · 2024: 421 · 2023: 284 · 2022: 63
- FWCI
- 181.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- tremelimumab, durvalumab, hepatocellular carcinoma, unresectable liver cancer, CTLA-4 blockade, PD-L1 blockade, sorafenib, overall survival, non-inferiority, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, treatment-emergent adverse events, immune-related adverse events, non-small cell lung cancer
- MeSH terms
- Antineoplastic Agents, Immunological, Sorafenib, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
